Aytu BioPharma, Inc.
AYTU · Price history
Price at last available close
$1.98
−$0.22 (-10.00%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Aytu BioPharma, Inc.
Primary reporting period: 2026-06-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U. S. and international markets.
How they make money
Aytu BioPharma generates revenue primarily through the commercialization and sale of prescription pharmaceutical products focused on complex central nervous system (CNS) diseases. The company utilizes its proprietary Aytu RxConnect patient support platform to facilitate patient access to its medicines by managing co-pays and coordinating with pharmacies to reduce barriers to treatment.
Products & services
The company's product portfolio includes prescription therapeutics for CNS conditions, such as EXXUA (brexpiprazole) for the treatment of major depressive disorder, and a portfolio of pediatric and adult ADHD medications including Adzenys XR-ODT, Cotempla XR-ODT, and Karbinal ER.
Brands & revenue mix
A prescription medication for the treatment of major depressive disorder.
Separate brand revenue is not available in this research.Source
An extended-release orally disintegrating tablet for the treatment of ADHD.
Separate brand revenue is not available in this research.Source
An extended-release orally disintegrating tablet for the treatment of ADHD.
Separate brand revenue is not available in this research.Source
An extended-release carbinoxamine maleate suspension for the treatment of allergic rhinitis and other conditions.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company typically relies on a limited number of wholesale distributors for the majority of its product distribution, which creates concentration risk regarding its revenue stream.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production and supply of its pharmaceutical products.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
25
Poor
Financial Strength
44
Business Quality / Moat
0
Management
40
Growth Quality
18
Risk / Durability
13
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
No strong positive signal is being highlighted from the currently available summary data.
- •Material dilution — approximately 96.2% share-count growth
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •CRITICAL: Bankruptcy / liquidation risk
- •Debt service risk
- •Valuation is a weaker part of the current profile
Company-specific research
Questions worth answering for AYTU
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AYTU maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is AYTU's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Does AYTU's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for AYTU to reach sustainable profitability?
- •What future growth or profitability would be needed to justify AYTU's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Market Cap
$21.5M
P/E Ratio
-1.8
EPS
$-1.16
52-Week High
$3.07
52-Week Low
$1.80
Beta
0.27
Shares Outstanding
12.3M
Total Revenue
$57.6M
Total Debt
$18.1M
Dividend
No current dividend
Liquidation Value / Share
$2.86
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AYTU
Detected from reported data — verify before acting.Material dilution — approximately 96.2% share-count growth
Shares outstanding increased approximately 96.2% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 45.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingDebt service risk
Interest coverage is low (~-4.4x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on AYTU.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary Aytu RxConnect patient support platform.
- +Focused portfolio of specialized CNS therapeutics.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Dependence on third-party contract manufacturers for product supply.
- −Significant customer concentration among wholesale distributors.
- −History of operating losses and need for additional capital.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
18
Sep 23, 2026
Change
Unchanged
Current Score
18
Oct 1, 2026
Category Changes
AYTU score was unchanged.
Positive Contributors
- + Debt improved by 58.1 points
- + Buffett improved by 14.5 points
Projected Score
Projected Score
19
Projected Change
+1.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 1.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.98
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57.6M | $57.6M | $66.4M | $65.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $20.8M | $20.8M | $20.6M | $16.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $36.8M | $36.8M | $45.8M | $49.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $1.3M | $2.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $42.6M | $42.6M | $38.3M | $42.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $45.1M | $45.1M | $53.7M | $50.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$8.5M | -$4.4M | -$4.7M | $1.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$8.3M | -$8.3M | -$7.8M | -$1.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.1M | -$1.9M | $3.7M | $4.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$14.2M | -$14.2M | -$13.7M | -$10.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$1K | -$21K | $437K | $2.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$14.3M | -$14.3M | -$13.6M | -$15.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.16 | $-1.16 | $-2.16 | $-2.86 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 12.32M | 12.32M | 6.28M | 5.54M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 12.32M | 12.32M | 6.28M | 5.54M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$16.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.00
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-21.1%
Cash Change
-15.0%
Margin Change
+130.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 6.4%. EPS declined 100.0%. Cash declined 15.0%. Total debt declined 21.1%. Net income margin improved by 130.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Rumor Mill · AYTU
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial